Aptevo appoints Lamothe COO, Taylor CFO; base salaries $470K and $404K

Aptevo Therapeutics Inc.

Jeffrey Lamothe promoted from EVP/CFO to EVP/COO; base salary $470,000, bonus target 45%.
Daphne Taylor promoted from SVP Finance to SVP/CFO; base salary $403,745, bonus target 40%.
Lamothe received 16,500 options and 16,500 RSUs vesting over 3 years under 2018 Stock Plan.
Taylor received 11,000 options and 11,000 RSUs vesting over 3 years; effective March 3, 2023.
No family relationships or reportable transactions involving the appointees.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jeffrey G. Lamothe

Executive Vice President, Chief Operating Officer

APVO · Aptevo Therapeutics Inc.

Effective: 2023-03-03
Filed: March 7, 2023, 6:59 PM ET

On March 3, 2023, Aptevo Therapeutics Inc. (the “Company”) appointed Jeffrey G. Lamothe, formerly the Company’s Executive Vice President, Chief Financial Officer, to Executive Vice President, Chief Operating Officer.

Role change

Daphne Taylor

Senior Vice President, Chief Financial Officer

APVO · Aptevo Therapeutics Inc.

Effective: 2023-03-03
Filed: March 7, 2023, 6:59 PM ET

Also, on March 3, 2023, the Company appointed Daphne Taylor, formerly the Company’s Senior Vice President, Finance, to Senior Vice President, Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey G. Lamothe was appointed as Executive Vice President, Chief Operating Officer at Aptevo Therapeutics Inc..

Action: appointed
Role: Executive Vice President, Chief Operating Officer

Exact text from the filing

On March 3, 2023, Aptevo Therapeutics Inc. (the “Company”) appointed Jeffrey G. Lamothe, formerly the Company’s Executive Vice President, Chief Financial Officer, to Executive Vice President, Chief Operating Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daphne Taylor was appointed as Senior Vice President, Chief Financial Officer at Aptevo Therapeutics Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer

Exact text from the filing

Also, on March 3, 2023, the Company appointed Daphne Taylor, formerly the Company’s Senior Vice President, Finance, to Senior Vice President, Chief Financial Officer.

View on SEC.gov

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006384

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.